Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint

Leukemia
E ArchimbaudR Rimokh

Abstract

Although the presence of a chromosome 11q23 breakpoint is of recognized poor prognosis in acute lymphoblastic leukemia, its prognostic significance in acute myeloid leukemia (AML) has been the object of conflicting reports, perhaps reflecting the possibility of different entities. It has been found that only typical and generally balanced 11q23 chromosomal anomalies involve the MLL gene while atypical and generally unbalanced do not. To determine whether these two categories of AML patients had different initial characteristics and evolution, supporting different pathogenetic mechanisms, we analyzed clinical and biologic characteristics of newly diagnosed AML patients with balanced 11q23 breakpoint and/or MLL rearrangement seen over a 10-year period in our institution and compared them to cases with unbalanced 11q23 anomaly seen over the same period. These two categories of patients were compared with newly diagnosed patients with normal karyotype and no MLL rearrangement when tested, seen over the same period of time and treated similarly. Over this period, 442 newly diagnosed adult (> 15 years) AML seen in our institution had a successful karyotype performed before any therapy. Thirty-six cases (8%) had a chromosome 11q23 bre...Continue Reading

Citations

Feb 22, 2005·Cancer Genetics and Cytogenetics·Nathalie Douet-GuilbertMarc De Braekeleer
Dec 31, 2002·Cancer Genetics and Cytogenetics·Ninette CohenAliza Amiel
Feb 25, 2000·Cancer Genetics and Cytogenetics·J PowellP M Rosoff
Aug 11, 2010·Bone Marrow Transplantation·M TobiassonJ Mattsson
Aug 10, 2000·British Journal of Haematology·D Y ZangF Appelbaum
Jan 25, 2003·British Journal of Haematology·David BowenUNKNOWN UK MDS Guidelines Group
Jan 10, 2003·Psychiatry and Clinical Neurosciences·Rie AkahoHisashi Sakamaki
Mar 12, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·Pierluigi PorcuMichael Bissell
May 26, 1999·The New England Journal of Medicine·M L Heaney, D W Golde
Dec 3, 2010·Journal of Clinical and Experimental Hematopathology : JCEH·Hayato Tamai, Koiti Inokuchi
Jun 10, 2000·British Journal of Haematology·C H Pui, M V Relling
Oct 24, 2000·Leukemia & Lymphoma·G VisaniS Tura
Nov 26, 2010·Expert Review of Hematology·Hau C Kwaan, Timothy Huyck
Jan 29, 2005·Cancer Genetics and Cytogenetics·Steven D P MoorePaola Dal Cin
Aug 30, 2006·Cancer Genetics and Cytogenetics·Irina StasevichOlga Aleinikova
May 18, 2001·Best Practice & Research. Clinical Haematology·K MrózekC D Bloomfield
Oct 11, 2014·PloS One·Sabry Mohamed AttiaSaleh Abdulrahman Bakheet
Aug 8, 2007·Mutation Research·A Kathleen McClendon, Neil Osheroff
Feb 18, 2012·Current Opinion in Genetics & Development·Lisa G ShafferBlake C Ballif
Feb 14, 2012·Chemico-biological Interactions·Joseph Wiemels
May 3, 2014·Critical Reviews in Oncology/hematology·Rebecca L Wright, Andrew T M Vaughan
Aug 29, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohamed L SorrorRainer Storb
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanJames F Holland
Feb 19, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin S TallmanUNKNOWN Eastern Cooperative Oncology Group
Nov 8, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea KuendgenUlrich Germing
Sep 11, 2014·Current Opinion in Oncology·Emily Bart-Smith, Ghulam J Mufti
Apr 23, 2013·Therapeutic Advances in Hematology·Cyrus KhanJames M Rossetti
Oct 27, 2017·Expert Review of Hematology·Roberto CastelliGiorgio Lambertenghi-Deliliers

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.